Difference between revisions of "Part:BBa K5412002"

 
 
Line 19: Line 19:
 
<partinfo>BBa_K5412002 parameters</partinfo>
 
<partinfo>BBa_K5412002 parameters</partinfo>
 
<!-- -->
 
<!-- -->
 +
<p>
 +
REFERENCES: <br>
 +
https://www.cell.com/molecular-therapy-family/methods/fulltext/S2329-0501(23)00120-1
 +
</p>

Latest revision as of 13:59, 2 October 2024


CFTR mutant

Design considerations for this sequence include selecting a strong, constitutive promoter for efficient CFTR gene expression, optimizing codon usage for target organisms, ensuring accurate regulatory elements for proper transcription, and incorporating necessary enhancers. Careful sequence validation is crucial to prevent mutations, ensuring the gene's function for Cystic Fibrosis research and therapeutic development.


Sequence and Features


Assembly Compatibility:
  • 10
    INCOMPATIBLE WITH RFC[10]
    Illegal EcoRI site found at 1
    Illegal EcoRI site found at 486
    Illegal EcoRI site found at 2903
    Illegal SpeI site found at 2681
  • 12
    INCOMPATIBLE WITH RFC[12]
    Illegal EcoRI site found at 1
    Illegal EcoRI site found at 486
    Illegal EcoRI site found at 2903
    Illegal SpeI site found at 2681
  • 21
    INCOMPATIBLE WITH RFC[21]
    Illegal EcoRI site found at 1
    Illegal EcoRI site found at 486
    Illegal EcoRI site found at 2903
  • 23
    INCOMPATIBLE WITH RFC[23]
    Illegal EcoRI site found at 1
    Illegal EcoRI site found at 486
    Illegal EcoRI site found at 2903
    Illegal SpeI site found at 2681
  • 25
    INCOMPATIBLE WITH RFC[25]
    Illegal EcoRI site found at 1
    Illegal EcoRI site found at 486
    Illegal EcoRI site found at 2903
    Illegal SpeI site found at 2681
  • 1000
    INCOMPATIBLE WITH RFC[1000]
    Illegal BsaI site found at 2705


REFERENCES:
https://www.cell.com/molecular-therapy-family/methods/fulltext/S2329-0501(23)00120-1